“Derived Multiple Allogeneic Protein Paracrine Signaling (d-MAPPS)” Enhances T Cell-Driven Immune Response to Murine Mammary Carcinoma
Open Access
- 15 June 2022
- journal article
- research article
- Published by Wiley in Analytical Cellular Pathology
- Vol. 2022, 1-10
Abstract
Breast cancer is considered refractory to immunotherapy. Accordingly, there is an urgent need for the therapeutic use of new immunostimulatory agents which would enhance antitumor immune response against breast cancer cells. Derived Multiple Allogeneic Protein Paracrine Signaling (d-MAPPS) is a biological product whose activity is based on chemokines and cytokines that modulate homing and phenotype of immune cells. d-MAPPS contains high concentration of dendritic cell (DC) and T cell-attracting chemokine CXCL16 and potent T cell-activating cytokine IL-27 which enhance DC:T cell cross-talk in inflamed tissues. Herewith, we used 4T1 murine model of breast cancer to analyze d-MAPPS-dependent enhancement of T cell-driven antitumor immunity. 4T1+d-MAPPS-treated mice showed delayed mammary tumor appearance compared to 4T1+saline-treated animals. d-MAPPS significantly reduced tumor weight and volume and improved survival of 4T1-treated mice. Significantly increased concentration of CXCL16, IL-27, IFN-γ, and IL-17 and decreased concentration of immunosuppressive TGF-β and IL-10 were measured in serum samples and tumor tissues of 4T1+d-MAPPS-treated mice. d-MAPPS enhanced production of IL-12 and increased expression of MHC class II and costimulatory molecules on tumor-infiltrated DC, significantly improving their antigen-presenting properties. d-MAPPS in CXCL16-dependent manner promoted recruitment of antitumorigenic IFN-γ/IL-17-producing CD4+Th1/Th17 cells and in IL-27-dependent manner induced expansion of tumoricidal CD178+granzyme B-expressing CD8+CTLs and inhibited generation of tolerogenic DC, IL-10, and TGF-β-producing FoxP3-expressing T regulatory cells. In summing up, d-MAPPS, in CXL16- and IL-27-dependent manner, enhanced T cell-driven antitumor immune response and suppressed breast cancer growth in experimental mice.Keywords
Funding Information
- Faculty of Medical Sciences University of Kragujevac (MP01/18, ON175103, ON175069, IZSEZ0 185546)
- Serbian Ministry of Science (MP01/18, ON175103, ON175069, IZSEZ0 185546)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (MP01/18, ON175103, ON175069, IZSEZ0 185546)
- European Crohn’s and Colitis Organization (MP01/18, ON175103, ON175069, IZSEZ0 185546)
This publication has 22 references indexed in Scilit:
- Recent advances in understanding antitumor immunityF1000Research, 2016
- Interleukin-27 in T Cell ImmunityInternational Journal of Molecular Sciences, 2015
- IL-27 in tumor immunity and immunotherapyTrends in Molecular Medicine, 2013
- Inhibition of IL-17A in Tumor Microenvironment Augments Cytotoxicity of Tumor-Infiltrating Lymphocytes in Tumor-Bearing MicePLOS ONE, 2013
- Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunityCancer Immunology, Immunotherapy, 2011
- The cytotoxic effects of some selected gold(III) complexes on 4T1 cells and their role in the prevention of breast tumor growth in BALB/c mice.2011
- Differentiation of Effector CD4 T Cell PopulationsAnnual Review of Immunology, 2010
- IL-27 Is a Key Regulator of IL-10 and IL-17 Production by Human CD4+ T CellsThe Journal of Immunology, 2009
- Tumor antigen-specific T helper cells in cancer immunity and immunotherapyCancer Immunology, Immunotherapy, 2005
- IL-27 and IFN- α Signal via Stat1 and Stat3 and Induce T-Bet and IL-12R β 2 in Naive T CellsJournal of Interferon & Cytokine Research, 2003